Homburger advised Alcon Inc. on its USD 1.5 bn acquisition of STAAR Surgical

On August 4, 2025, Alcon Inc. (SIX/NYSE: ALC), the global leader in eye care, and STAAR Surgical Company (NASDAQ: STAA), the manufacturer of the Implantable Collamer® Lens for vision correction (ICL), entered into a definitive merger agreement through which Alcon intends to acquire STAAR, for a total equity value of approximately USD 1.5 bn. The acquisition includes the EVO family of lenses (EVO ICL™) for vision correction for patients with moderate to high myopia (nearsightedness), with or without astigmatism.

The transaction is anticipated to close in approximately six to 12 months, subject to customary closing conditions, including regulatory approval and approval by STAAR’s shareholders.

The Homburger team was led by Frank Gerhard (Corporate / M&A) and included Héloïse de Jamblinne and Thomas Romelli (both Corporate / M&A), Jeremy Reichlin (Employment and Executive Compensation), Jürg Frick and Nathalie Scherrer (both Financing), as well as Stefan Oesterhelt and Adrian Schwarz (both Tax).